Saltar al contenido
Merck

SML2075

Sigma-Aldrich

Gimeracil

≥98% (HPLC)

Sinónimos:

5-Chloropyridine-2,4-diol, 5-chloro-4-hydroxypyridin-2(1H)-one, CDHP, Gimestat

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C5H4ClNO2
Número de CAS:
Peso molecular:
145.54
Número MDL:
Código UNSPSC:
12352200
NACRES:
NA.77

Análisis

≥98% (HPLC)

formulario

powder

color

white to brown

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

−20°C

InChI

1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)

Clave InChI

ZPLQIPFOCGIIHV-UHFFFAOYSA-N

Acciones bioquímicas o fisiológicas

Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an orally active inhibitor against dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine and the chemotherapeutic drug 5-fluorouracil (5FU). Gimeracil is shown to exhibit cancer-radiosensitizing efficacy in cultures in vitro (1 mM) and in mice in vivo (2.5-25 mg/kg, p.o.) in a DPYD-dependent manner via partial suppression of DNA repair by homologous recombination (HR).

Pictogramas

Exclamation mark

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Keiji Koda et al.
Anticancer research, 36(10), 5325-5331 (2016-11-01)
It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy
Masakazu Fukushima et al.
Oncology reports, 24(5), 1307-1313 (2010-09-30)
Chemoradiotherapy is a useful treatment strategy in patients with locally advanced cancers. In particular, combination of 5-fluorouracil (5-FU) with X-ray irradiation is effective for the treatment of some types of gastrointestinal cancers. We investigated the antitumor effects of combination treatment
T Wang et al.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 20(3), 181-186 (2016-04-14)
This study evaluated the efficacy and safety of the combination drug tegafur, gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Patients with pathologically or cytologically newly
Ryohei Nishiguchi et al.
BMJ case reports, 2016 (2016-12-10)
The most common histological classification of bile duct cancer is adenocarcinoma and squamous cell carcinoma (SCC) is relatively rare. We report a case of a 78-year-old man with SCC of the extrahepatic bile duct associated with metachronous para-aortic lymph node
Koh-Ichi Sakata et al.
Cancer science, 102(9), 1712-1716 (2011-06-15)
Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. Gimeracil was originally added to an oral fluoropyrimidine derivative S-1 to yield prolonged 5-fluorouracil concentrations in serum and tumor tissues. We have

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico